Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript May 8, 2025Crinetics Pharmaceuticals, Inc. misses on earnings expectations.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 6,239,902 | $209,286,313 | +2% | 2.02% |
| 2. | Farallon Capital Thomas Steyer | 4,605,098 | $154,454,987 | +14% | 0.86% |
| 3. | EcoR1 Capital Oleg Nodelman | 4,288,120 | $143,823,545 | 8.53% | |
| 4. | Siren L.L.C. Raymond Debbane | 1,688,611 | $56,636,013 | +5% | 3.19% |
| 5. | Vestal Point Capital Ryan Wilder | 1,500,000 | $50,310,000 | 3.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | $110,300.00 | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | $3,499,983.30 | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | $23,760,000.00 | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | $4,999,995.84 | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | $52,400.00 | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.23 | 97,483 | $3,141,877.09 | 99,713 | 2025-06-12 | Filing | |
| $34.83 | 127 | $4,423.41 | 72,233 | 2025-03-19 | Filing | |
| $34.17 | 2,388 | $81,597.96 | 72,360 | 2025-03-19 | Filing | |
| $34.83 | 361 | $12,573.63 | 87,491 | 2025-03-19 | Filing | |
| $34.17 | 6,801 | $232,390.17 | 87,852 | 2025-03-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,031,269 | $470,608,761 | 0.03% | |
| 2. | 9,311,600 | $312,311,064 | 0.01% | |
| 3. | 7,656,569 | $256,801,325 | 0.01% | |
| 4. | 6,891,397 | $231,137,455 | 0.04% | |
| 5. | 3,424,442 | $118,895,467 | 0.07% |
News See All
11 Stocks That Will Bounce Back According to Analysts
Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone. Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call.
10 Worst Performing Mid Cap Stocks to Buy According to Analysts
Market analysts are increasingly highlighting mid-cap stocks as a potentially attractive investment opportunity, particularly in the current economic climate.
15 Stocks That Took a Nosedive in January
Historically, the S&P 500's performance in January sets the pace for the rest of the year.
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2024 Earnings Call Transcript
Operator: Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this call may be recorded.
Billionaire Hedge Funds
